Complication | Evidence | PMID |
Nephropathy | 1. This study investigated whether SPR ameliorates nephropathy by increasing G6PD activity and reducing oxidative stress in spontaneously hypertensive diabetic rats (SHRs). | 21987533 |
Cardiovascular | 1. Thus G6PD may be a useful therapeutic target for treating the cardiovascular disease associated with type 2 diabetes, if second-generation drugs specifically reducing the activity of G6PD to near normal levels are developed | 19429815 |
Neuropathy | 1. The frequency of G6PD deficiency in patients with NAION was significantly lower than expected. suggest that G6PD-deficient patients in the Sardinian population have a significantly decreased risk of having NAION. | 18385045 |
Retinopathy | 1. Poor glycemia levels along with increased generation of ALEs might be the major contributing biochemical derangements associated with decreased G6PD activity followed by low NADPH levels in subjects with MNPDR, thus increasing the vulnerability of erythrocytes to oxidative stress in the early course of retinopathy. | 27916496 |
Insulin resistance and inflammation | 1. Adipogenic G6PD overexpression promotes the expression of pro-oxidative enzymes, including inducible nitric oxide synthase and NADPH oxidase, and the activation of nuclear factor-kappaB (NF-kappaB) signaling, which eventually leads to the dysregulation of adipocytokines and inflammatory signals. | 17065329 |